ClearPoint Neuro, Inc.
NASDAQ•CLPT
CEO: Mr. Joseph Michael Burnett
セクター: Healthcare
業種: Medical - Devices
上場日: 2012-05-22
ClearPoint Neuro, Inc. operates as a medical device company primarily in the United States. It develops and commercializes platforms for performing minimally invasive surgical procedures in the brain under magnetic resonance imaging guided interventions. The company offers ClearPoint system, an integrated system for the insertion of deep brain stimulation electrodes, biopsy needles, and laser catheters, as well as the infusion of pharmaceuticals into the brain. It has license and collaboration agreement with Clinical Laserthermia Systems AB; license and research agreement with Koninklijke Philips N.V., UCB Biopharma SRL, and University of California and San Francisco; and development and license agreement with NE Scientific, LLC. The company was formerly known as MRI Interventions, Inc. and changed its name to ClearPoint Neuro, Inc. in February 2020. ClearPoint Neuro, Inc. was incorporated in 1998 and is headquartered in Solana Beach, California.
連絡先情報
120 S. Sierra Avenue, Suite 100, Solana Beach, CA, 92075, United States
888-287-9109
時価総額
$336.75M
PER (TTM)
-13.9
27
配当利回り
--
52週高値
$30.10
52週安値
$8.63
52週レンジ
順位55Top 80.0%
2.6
F-Score
改良版 Piotroski 分析
10年ファンダメンタル
弱い • 2.6 / 9 ポイント
スコアレンジ (0-9)
8-9: 価値が優れている
6-7: 基礎体質が強い
4-5: 全体的に堅調
0-3: パフォーマンスが弱い
データ期間: 2016-2025
財務ダッシュボード
Q3 2025 データ
売上高
$8.86M+9.10%
直近4四半期の推移
EPS
-$0.21+16.67%
直近4四半期の推移
フリーCF
-$3.32M+174.15%
直近4四半期の推移
2025 Q3 決算ハイライト
主なハイライト
Total Revenue Increased 9% Q3 2025 total revenue reached $8.9M, a 9% increase; 9M revenue grew 12% to $26.6M.
Gross Margin Expansion Noted Q3 Gross Margin improved to 63% compared to 60% last year, driven by favorable revenue mix.
Secured Major Debt Financing Secured $28.7M net proceeds from 2025 NPA issuance, supplementing $3.3M from 2025 SPA offering.
Service Revenue Strong Growth Q3 Service revenue surged 32% to $3.5M, offsetting slight product revenue decline for the quarter.
リスク要因
Net Loss Widened Significantly Q3 Net Loss increased 18% to $(5.9M); 9M Net Loss widened 31% to $(17.8M).
Operating Expenses Increased Nine months G&A expenses rose 27% to $11.1M, driven by higher personnel and professional fees.
Debt Covenants Exposure Obligations under 2025 NPA include covenants; failure to comply risks acceleration of outstanding debt principal.
Biologics Regulatory Uncertainty Growth in biologics business depends on timely FDA approval and evolving regulatory criteria for CGTs.
見通し
IRRAS Acquisition Expected Closing Merger Agreement signed November 6, 2025, with expected closing in the fourth quarter of 2025.
Additional Funding Contingent Agreement secured to access $20.0M additional funding contingent upon successful closing of IRRAS transaction.
Liquidity Position Adequate Management believes current cash balances of $38.2M are sufficient for operations over next twelve months.
Biologics Partner Base Expanding Partner relationships for biologics/drug delivery grew to over 60 as of September 30, 2025.
同業比較
売上高 (TTM)
$912.10M
$854.40M
$824.50M
粗利益率 (最新四半期)
83.5%
79.0%
78.8%
主要指標
銘柄コード | 時価総額 | PER (TTM) | ROE (TTM) | 負債比率 |
|---|---|---|---|---|
| TYRA | $1.85B | -17.3 | -41.2% | 2.1% |
| AXGN | $1.59B | -91.7 | -13.4% | 8.7% |
| OLMA | $1.24B | -9.0 | -41.5% | 1.3% |
長期トレンド
直近4四半期
売上高
純利益
営業キャッシュフロー
4四半期売上高CAGR
4.5%
緩やかな成長
4四半期純利益CAGR
N/M
収益構造の変化
キャッシュフロー安定性
0%
キャッシュフローに注意が必要
深度リサーチ
次回決算:2026年3月11日
EPS:-$0.22
|売上高:$10.05M
財務データ
決算説明会
財務レポート
ニュース
損益計算書
バランスシート
キャッシュフロー計算書
財務比率
変化率
損益計算書 | 直近12ヶ月 |
|---|
データなし